Mark Eisner has sold stock and made no open-market buys since Mar 2023

Mark D. Eisner, M.D., M.P.H. serves as Executive Vice President and Chief Medical Officer (CMO) at Vir Biotechnology, Inc., a position he has held since June 2024( A seasoned biotechnology executive with more than 25 years of leadership in clinical development and immunology( Dr. Eisner brings extensive expertise in infectious disease and immunology with a proven track record of advancing late-stage clinical candidates to market. He is responsible for leading Translational and Clinical Development, including Clinical Research, Development Operations, Biometrics, Clinical Pharmacology, Pharmacovigilance, and Risk Management, as well as Medical Affairs and Regulatory Affairs(

Prior to joining Vir, Dr. Eisner held the position of CMO at Sonoma Biotherapeutics, where he oversaw all development functions( He previously served as CMO at FibroGen, including as Head of China Clinical Development and Clinical Operations( Dr. Eisner spent nearly 11 years at Genentech, where he rose to Senior Vice President and Global Head of Product Development for Immunology, Infectious Disease, and Ophthalmology, leading late-stage clinical development across multiple product candidates( He earned his A.B. in human biology from Stanford University, his M.D. from the University of Pennsylvania School of Medicine, and his M.P.H. with a focus on epidemiology from the University of California Berkeley School of Public Health(

Written by Perplexity from public sources.